This is a preview of subscription content, log in via an institution to check access.
Reference
Mearns E, et al. Cost-effectiveness of high-dose edoxaban compared to adjusted-dose warfarin for prevention of stroke and systemic embolism in non-valvular atrial fibrillation. ESC Congress 2014: Annual Congress of the European Society of Cardiology : abstr. 5110, 14 Aug 2014. Available from: URL: http://www.escardio.org/congresses/esc-2014
Rights and permissions
About this article
Cite this article
Edoxaban cost-effective option in NVAF. PharmacoEcon Outcomes News 712, 16 (2014). https://doi.org/10.1007/s40274-014-1561-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1561-0